The U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for the Symbiotica COVID-19 Self-Collected Antibody Test System, which the agency said is the first antibody test authorized for use with home collected dried blood spot samples, according to a news release.
Samples collected at home are then sent to a Symbiotica’s laboratory for analysis.
“The authorization of the first prescription use, home collection antibody test will play an important role in helping health care professionals identify individuals who have developed an adaptive immune response from a recent or prior COVID-19 infection,” said Jeff Shuren, MD, JD, Director of the FDA’s Center for Devices and Radiological Health. “The FDA will continue to authorize COVID-19 tests that will give more Americans access to greater testing flexibility and options.”
The COVID-19 Self-Collected Antibody Test System is authorized for prescription use with a fingerstick dried-blood sample that is self-collected by an individual age 18 years or older or collected by an adult from an individual 5 years of age and older. The test is intended to aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection. The COVID-19 Self-Collected Antibody Test System should not be used to diagnose or exclude acute SARS-CoV-2 infection. At this time, it is unknown how long antibodies persist following infection and if the presence of antibodies confers protective immunity.
